دورية أكاديمية
SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy.
العنوان: | SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy. |
---|---|
المؤلفون: | Baars AE; From the Department of Neurology (A.E.B., K.K., L.C.K., L.W.G.L., W.M.K., B.C.J., P.A.D.), Erasmus MC University Medical Center, Rotterdam; Department of Neurology (K.K.), Albert Schweitzer Hospital, Dordrecht; Department of Neurology (L.W.G.L.), St. Elisabeth-TweeSteden Hospital, Tilburg; Department of Neurology (F.E., L.W.), Amsterdam University Medical Center, University of Amsterdam; Department of Neurology and Neurosurgery (H.S.G., W.L.P.), Brain Center University Medical Center Utrecht; Dutch Patient Organization for Neuromuscular Diseases (P.H.B.-M., A.M.C.H.), Baarn; and Department of Immunology (B.C.J.), Erasmus MC University Medical Center, Rotterdam, the Netherlands., Kuitwaard K; From the Department of Neurology (A.E.B., K.K., L.C.K., L.W.G.L., W.M.K., B.C.J., P.A.D.), Erasmus MC University Medical Center, Rotterdam; Department of Neurology (K.K.), Albert Schweitzer Hospital, Dordrecht; Department of Neurology (L.W.G.L.), St. Elisabeth-TweeSteden Hospital, Tilburg; Department of Neurology (F.E., L.W.), Amsterdam University Medical Center, University of Amsterdam; Department of Neurology and Neurosurgery (H.S.G., W.L.P.), Brain Center University Medical Center Utrecht; Dutch Patient Organization for Neuromuscular Diseases (P.H.B.-M., A.M.C.H.), Baarn; and Department of Immunology (B.C.J.), Erasmus MC University Medical Center, Rotterdam, the Netherlands., de Koning LC; From the Department of Neurology (A.E.B., K.K., L.C.K., L.W.G.L., W.M.K., B.C.J., P.A.D.), Erasmus MC University Medical Center, Rotterdam; Department of Neurology (K.K.), Albert Schweitzer Hospital, Dordrecht; Department of Neurology (L.W.G.L.), St. Elisabeth-TweeSteden Hospital, Tilburg; Department of Neurology (F.E., L.W.), Amsterdam University Medical Center, University of Amsterdam; Department of Neurology and Neurosurgery (H.S.G., W.L.P.), Brain Center University Medical Center Utrecht; Dutch Patient Organization for Neuromuscular Diseases (P.H.B.-M., A.M.C.H.), Baarn; and Department of Immunology (B.C.J.), Erasmus MC University Medical Center, Rotterdam, the Netherlands., Luijten LWG; From the Department of Neurology (A.E.B., K.K., L.C.K., L.W.G.L., W.M.K., B.C.J., P.A.D.), Erasmus MC University Medical Center, Rotterdam; Department of Neurology (K.K.), Albert Schweitzer Hospital, Dordrecht; Department of Neurology (L.W.G.L.), St. Elisabeth-TweeSteden Hospital, Tilburg; Department of Neurology (F.E., L.W.), Amsterdam University Medical Center, University of Amsterdam; Department of Neurology and Neurosurgery (H.S.G., W.L.P.), Brain Center University Medical Center Utrecht; Dutch Patient Organization for Neuromuscular Diseases (P.H.B.-M., A.M.C.H.), Baarn; and Department of Immunology (B.C.J.), Erasmus MC University Medical Center, Rotterdam, the Netherlands., Kok WM; From the Department of Neurology (A.E.B., K.K., L.C.K., L.W.G.L., W.M.K., B.C.J., P.A.D.), Erasmus MC University Medical Center, Rotterdam; Department of Neurology (K.K.), Albert Schweitzer Hospital, Dordrecht; Department of Neurology (L.W.G.L.), St. Elisabeth-TweeSteden Hospital, Tilburg; Department of Neurology (F.E., L.W.), Amsterdam University Medical Center, University of Amsterdam; Department of Neurology and Neurosurgery (H.S.G., W.L.P.), Brain Center University Medical Center Utrecht; Dutch Patient Organization for Neuromuscular Diseases (P.H.B.-M., A.M.C.H.), Baarn; and Department of Immunology (B.C.J.), Erasmus MC University Medical Center, Rotterdam, the Netherlands., Eftimov F; From the Department of Neurology (A.E.B., K.K., L.C.K., L.W.G.L., W.M.K., B.C.J., P.A.D.), Erasmus MC University Medical Center, Rotterdam; Department of Neurology (K.K.), Albert Schweitzer Hospital, Dordrecht; Department of Neurology (L.W.G.L.), St. Elisabeth-TweeSteden Hospital, Tilburg; Department of Neurology (F.E., L.W.), Amsterdam University Medical Center, University of Amsterdam; Department of Neurology and Neurosurgery (H.S.G., W.L.P.), Brain Center University Medical Center Utrecht; Dutch Patient Organization for Neuromuscular Diseases (P.H.B.-M., A.M.C.H.), Baarn; and Department of Immunology (B.C.J.), Erasmus MC University Medical Center, Rotterdam, the Netherlands., Wieske L; From the Department of Neurology (A.E.B., K.K., L.C.K., L.W.G.L., W.M.K., B.C.J., P.A.D.), Erasmus MC University Medical Center, Rotterdam; Department of Neurology (K.K.), Albert Schweitzer Hospital, Dordrecht; Department of Neurology (L.W.G.L.), St. Elisabeth-TweeSteden Hospital, Tilburg; Department of Neurology (F.E., L.W.), Amsterdam University Medical Center, University of Amsterdam; Department of Neurology and Neurosurgery (H.S.G., W.L.P.), Brain Center University Medical Center Utrecht; Dutch Patient Organization for Neuromuscular Diseases (P.H.B.-M., A.M.C.H.), Baarn; and Department of Immunology (B.C.J.), Erasmus MC University Medical Center, Rotterdam, the Netherlands., Goedee HS; From the Department of Neurology (A.E.B., K.K., L.C.K., L.W.G.L., W.M.K., B.C.J., P.A.D.), Erasmus MC University Medical Center, Rotterdam; Department of Neurology (K.K.), Albert Schweitzer Hospital, Dordrecht; Department of Neurology (L.W.G.L.), St. Elisabeth-TweeSteden Hospital, Tilburg; Department of Neurology (F.E., L.W.), Amsterdam University Medical Center, University of Amsterdam; Department of Neurology and Neurosurgery (H.S.G., W.L.P.), Brain Center University Medical Center Utrecht; Dutch Patient Organization for Neuromuscular Diseases (P.H.B.-M., A.M.C.H.), Baarn; and Department of Immunology (B.C.J.), Erasmus MC University Medical Center, Rotterdam, the Netherlands., van der Pol WL; From the Department of Neurology (A.E.B., K.K., L.C.K., L.W.G.L., W.M.K., B.C.J., P.A.D.), Erasmus MC University Medical Center, Rotterdam; Department of Neurology (K.K.), Albert Schweitzer Hospital, Dordrecht; Department of Neurology (L.W.G.L.), St. Elisabeth-TweeSteden Hospital, Tilburg; Department of Neurology (F.E., L.W.), Amsterdam University Medical Center, University of Amsterdam; Department of Neurology and Neurosurgery (H.S.G., W.L.P.), Brain Center University Medical Center Utrecht; Dutch Patient Organization for Neuromuscular Diseases (P.H.B.-M., A.M.C.H.), Baarn; and Department of Immunology (B.C.J.), Erasmus MC University Medical Center, Rotterdam, the Netherlands., Blomkwist-Markens PH; From the Department of Neurology (A.E.B., K.K., L.C.K., L.W.G.L., W.M.K., B.C.J., P.A.D.), Erasmus MC University Medical Center, Rotterdam; Department of Neurology (K.K.), Albert Schweitzer Hospital, Dordrecht; Department of Neurology (L.W.G.L.), St. Elisabeth-TweeSteden Hospital, Tilburg; Department of Neurology (F.E., L.W.), Amsterdam University Medical Center, University of Amsterdam; Department of Neurology and Neurosurgery (H.S.G., W.L.P.), Brain Center University Medical Center Utrecht; Dutch Patient Organization for Neuromuscular Diseases (P.H.B.-M., A.M.C.H.), Baarn; and Department of Immunology (B.C.J.), Erasmus MC University Medical Center, Rotterdam, the Netherlands., Horemans AMC; From the Department of Neurology (A.E.B., K.K., L.C.K., L.W.G.L., W.M.K., B.C.J., P.A.D.), Erasmus MC University Medical Center, Rotterdam; Department of Neurology (K.K.), Albert Schweitzer Hospital, Dordrecht; Department of Neurology (L.W.G.L.), St. Elisabeth-TweeSteden Hospital, Tilburg; Department of Neurology (F.E., L.W.), Amsterdam University Medical Center, University of Amsterdam; Department of Neurology and Neurosurgery (H.S.G., W.L.P.), Brain Center University Medical Center Utrecht; Dutch Patient Organization for Neuromuscular Diseases (P.H.B.-M., A.M.C.H.), Baarn; and Department of Immunology (B.C.J.), Erasmus MC University Medical Center, Rotterdam, the Netherlands., Jacobs BC; From the Department of Neurology (A.E.B., K.K., L.C.K., L.W.G.L., W.M.K., B.C.J., P.A.D.), Erasmus MC University Medical Center, Rotterdam; Department of Neurology (K.K.), Albert Schweitzer Hospital, Dordrecht; Department of Neurology (L.W.G.L.), St. Elisabeth-TweeSteden Hospital, Tilburg; Department of Neurology (F.E., L.W.), Amsterdam University Medical Center, University of Amsterdam; Department of Neurology and Neurosurgery (H.S.G., W.L.P.), Brain Center University Medical Center Utrecht; Dutch Patient Organization for Neuromuscular Diseases (P.H.B.-M., A.M.C.H.), Baarn; and Department of Immunology (B.C.J.), Erasmus MC University Medical Center, Rotterdam, the Netherlands., van Doorn PA; From the Department of Neurology (A.E.B., K.K., L.C.K., L.W.G.L., W.M.K., B.C.J., P.A.D.), Erasmus MC University Medical Center, Rotterdam; Department of Neurology (K.K.), Albert Schweitzer Hospital, Dordrecht; Department of Neurology (L.W.G.L.), St. Elisabeth-TweeSteden Hospital, Tilburg; Department of Neurology (F.E., L.W.), Amsterdam University Medical Center, University of Amsterdam; Department of Neurology and Neurosurgery (H.S.G., W.L.P.), Brain Center University Medical Center Utrecht; Dutch Patient Organization for Neuromuscular Diseases (P.H.B.-M., A.M.C.H.), Baarn; and Department of Immunology (B.C.J.), Erasmus MC University Medical Center, Rotterdam, the Netherlands. p.a.vandoorn@erasmusmc.nl. |
المصدر: | Neurology [Neurology] 2023 Jan 10; Vol. 100 (2), pp. e182-e191. Date of Electronic Publication: 2022 Sep 20. |
نوع المنشور: | Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't |
اللغة: | English |
بيانات الدورية: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0401060 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1526-632X (Electronic) Linking ISSN: 00283878 NLM ISO Abbreviation: Neurology Subsets: MEDLINE |
أسماء مطبوعة: | Publication: Hagerstown, MD : Lippincott Williams & Wilkins Original Publication: Minneapolis. |
مواضيع طبية MeSH: | COVID-19*/prevention & control , COVID-19 Vaccines*/adverse effects , Guillain-Barre Syndrome*/epidemiology , Guillain-Barre Syndrome*/etiology , Guillain-Barre Syndrome*/diagnosis , Polyradiculoneuropathy, Chronic Inflammatory Demyelinating*/diagnosis, Humans ; Cohort Studies ; Prospective Studies ; SARS-CoV-2 ; Vaccination/adverse effects |
مستخلص: | Background and Objectives: There are concerns on the safety of SARS-CoV-2 vaccination in patients with a history of Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN). The aim of this study was to determine the risk of recurrence of GBS and exacerbations of CIDP or MMN after SARS-CoV-2 vaccination. Methods: We conducted a prospective, multicenter cohort study from January 2021 to August 2021. Patients known in 1 of 3 Dutch University Medical Centers with research focus on immune-mediated neuropathy and members of the Dutch Patient Association for Neuromuscular Diseases were invited to participate if they were 18 years or older and diagnosed with GBS, CIDP, or MMN. Participants completed a series of questionnaires at 4 different time points: study baseline (1), within 48 hours before any SARS-CoV-2 vaccination (2 and 3, if applicable), and 6 weeks after their last vaccination (4). Participants unwilling to get vaccinated completed the last questionnaire (4) 4 months after study baseline. We assessed recurrences of GBS, any worsening of CIDP or MMN-related symptoms, treatment alterations, and hospitalization. Results: Of 1,152 individuals to whom we sent the questionnaires, 674 (59%) signed informed consent. We excluded 153 individuals, most often because they had already received a SARS-CoV-2 vaccination or had had the infection (84%) before study baseline. Of 521 participants included in analyses, 403 (81%) completed the last questionnaire (time point 4). None of 162 participants with a history of GBS had a recurrence after vaccination. Of 188 participants with CIDP, 10 participants (5%) reported a worsening of symptoms within 6 weeks after vaccination. In 5 (3%) of these patients, maintenance treatment was modified. Two of 53 participants with MMN (4%) reported a worsening of symptoms, and treatment modification was reported by 1 participant. Discussion: We found no increased risk of GBS recurrence and a low to negligible risk of worsening of CIDP or MMN-related symptoms after SARS-CoV-2 vaccination. Based on our data, SARS-CoV-2 vaccination in patients with these immune-mediated neuropathies seems to be safe. (© 2022 American Academy of Neurology.) |
التعليقات: | Comment in: Neurology. 2023 Jan 10;100(2):55-56. (PMID: 36127140) Comment in: Neurology. 2023 Jul 4;101(1):50-51. (PMID: 37400257) Comment in: Neurology. 2023 Jul 4;101(1):51. (PMID: 37400258) |
المشرفين على المادة: | 0 (COVID-19 Vaccines) |
تواريخ الأحداث: | Date Created: 20220920 Date Completed: 20230112 Latest Revision: 20230705 |
رمز التحديث: | 20230705 |
DOI: | 10.1212/WNL.0000000000201376 |
PMID: | 36127144 |
قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!